Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000295337

Medchemexpress LLC GlyH-101 | 328541-79-3 | MFCD01532954 | 99.7% | 493.15 g/mol | C19H15Br2N3O3 | 10 MG
SDP

Catalog No. 5000295337
Encompass_Preferred

GlyH-101 is a research-grade small-molecule inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR). It is used in cellular and electrophysiological studies to block CFTR-mediated chloride conductance and has reported antiproliferative activity. Supplied as a purified, characterized compound for laboratory research.

  • Potent CFTR inhibitor for cellular and electrophysiology assays.
  • Reversible blockade of VSORC conductance.
  • High purity (99.7%).
  • Molecular weight 493.15 g/mol.
  • Molecular formula C19H15Br2N3O3.
  • Supplied as a 10 mg vial for research use.

Catalog No. 50-002-95337 Supplier Medchemexpress LLC Supplier No. HY1833610MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

GlyH-101 is a research-grade small-molecule inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR). It is used in cellular and electrophysiological studies to block CFTR-mediated chloride conductance and has reported antiproliferative activity. Supplied as a purified, characterized compound for laboratory research.

  • Potent CFTR inhibitor for cellular and electrophysiology assays.
  • Reversible blockade of VSORC conductance.
  • High purity (99.7%).
  • Molecular weight 493.15 g/mol.
  • Molecular formula C19H15Br2N3O3.
  • Supplied as a 10 mg vial for research use.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.